When your liver produces IGF-1 in response to growth hormone, that IGF-1 immediately binds to carrier proteins called insulin-like growth factor-binding proteins
Bethesda (MD): National Institutes of Health (US)
Medical contraindications and usewithcaution groups Even if regulators dont ban it outright, clinicians and safetyreview papers suggest avoiding or proceeding with extreme caution if you have: Active pancreatitis or high risk of pancreatitis Preclinical work links some GLP1like pathways (relevant to BPC157 formulations) with pancreatitis risk
this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
20 units = 0.2mL 3mg/mL = 0.6mg per injection
Related: GHK-Cu: The 2026 Copper Peptide Guide the full compound breakdown, dosing forms, and how to access it
